Enfermedad residual mínima (DRM) basada en el ADNc — seguimiento posterior al tratamiento
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BIO-CTDNA-MRD-POST-TREATMENT |
|---|---|
| Tipo | Biomarcador |
| Aliaces | ctDNA seguimiento MRDctDNA MRD post-tratamientoenfermedad molecular residual post-tratamientoSerie de CDNA MRDцтДНК-MRD — моніторинг після лікування |
| Situación | reviewed 2026-05-18 | pending_clinical_signoff |
| Enfermedades | DIS-BREAST DIS-CRC |
| Fuentes | SRC-CIVIC SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025 |
Datos sobre biomarcadores
| Tipo de biomarcador | composite_score |
|---|---|
| Medición | MétodoBiopsia líquida seria (plasma cfDNA): informada por tumor (Signatera, RaDaR, NeXT Personal — panel multilocus específico del paciente de la EAM tumoral primario) O ensayo de ADN ct de panel fijo tumor-agnóstico Unidadescategorical (MRD-positive | MRD-negative) + quantitative (mean tumor molecules per mL plasma, MTM/mL, or VAF) |
| Productos químicos y químicos | BIO-CTDNA-MRD |
Notas
Companion entry to BIO-CTDNA-MRD focused on POST-TREATMENT serial surveillance (vs. single landmark timepoint). Distinct from MCED (BIO-CFDNA-METHYLATION-MCED) in that ctDNA-MRD assumes a known prior cancer diagnosis with post-curative-intent surgery / chemoradiation. Strongest evidence in CRC (GALAXY / CIRCULATE-Japan, Kotani Nat Med 2023): MRD-positive post-op patients ~22% 18-mo DFS vs ~93% MRD- negative; MRD-positive benefit from adjuvant chemotherapy. Emerging evidence in muscle-invasive bladder cancer (IMvigor010 ctDNA subgroup), early breast cancer (c-TRAK-TN), NSCLC (post-IMpower010 retrospectives), pancreatic, gastric. Trial frameworks for MRD-driven escalation/de-escalation: CIRCULATE-Japan ALTAIR/VEGA, NRG-GI008 (CIRCULATE-US), DYNAMIC-IV. ESMO 2024 endorses ctDNA-MRD as a prognostic biomarker for CRC stage II adjuvant decision-making (May inform adjuvant chemo discussion when MRD+ at 4-8 weeks post-op). NOT recommended for asymptomatic-population screening — entry is surveillance of KNOWN prior cancer survivors. `applicable_in_asymptomatic: false` — patient has documented cancer history, not asymptomatic in the prevention sense. Caveats: assay LOD ~0.01% VAF, micrometa...
Utilizado por
Relevancia terapéutica
BMA-CTDNA-MRD-POST-TREATMENT-BREAST- Ensayos de ADNc personalizados para detectar MRD antes de recurr...BMA-CTDNA-MRD-POST-TREATMENT-CRC- Post-resection ctDNA-MRD positivity in stage II/III colorectal cancer identifies patients...